Condition: Non Small Cell Lung Cancer · Sponsor: Shanghai Henlius Biotech
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This description comes directly from the study's public registry record.
Jie He, Dr · +86 10-87788207 · hejie@cicams.ac.cn
Always discuss trial participation with your own doctor first.
| MD Anderson Cancer Hospital | Houston, Texas, United States | Not Yet Recruiting |
| National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06907615